These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 25444411

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH, Kim W, Li XF, Jung IJ, Kim HJ.
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y, Chang H, Zhang X, Yin L.
    Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
    [Abstract] [Full Text] [Related]

  • 24. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    Annovazzi P, Capobianco M, Moiola L, Patti F, Frau J, Uccelli A, Centonze D, Perini P, Tortorella C, Prosperini L, Lus G, Fuiani A, Falcini M, Martinelli V, Comi G, Ghezzi A.
    J Neurol; 2016 Sep; 263(9):1727-35. PubMed ID: 27286847
    [Abstract] [Full Text] [Related]

  • 25. Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO).
    Vaknin-Dembinsky A, Charbit H, Brill L, Abramsky O, Gur-Wahnon D, Ben-Dov IZ, Lavon I.
    J Neuroinflammation; 2016 Jul 08; 13(1):179. PubMed ID: 27393339
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Capillary leak syndrome in neuromyelitis optica treated with rituximab.
    Fuentes Fernandez I, Hernandez-Clares R, Carreón Guarnizo E, Meca Lallana JE.
    Mult Scler Relat Disord; 2017 Aug 08; 16():22-23. PubMed ID: 28755680
    [Abstract] [Full Text] [Related]

  • 28. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
    Pellkofer HL, Suessmair C, Schulze A, Hohlfeld R, Kuempfel T.
    Mult Scler; 2009 Aug 08; 15(8):1006-8. PubMed ID: 19667025
    [Abstract] [Full Text] [Related]

  • 29. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
    Mealy MA, Kim SH, Schmidt F, López R, Jimenez Arango JA, Paul F, Wingerchuk DM, Greenberg BM, Kim HJ, Levy M.
    Mult Scler; 2018 Nov 08; 24(13):1737-1742. PubMed ID: 28857723
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of rituximab in refractory neuromyelitis optica.
    Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R, OFSEP and CFSEP.
    Mult Scler; 2016 Jun 08; 22(7):955-9. PubMed ID: 26362900
    [Abstract] [Full Text] [Related]

  • 31. [Trial of rituximab in three patients with neuromyelitis optica].
    Imamura H, Tanaka M, Kitagawa N, Tahara M, Oono M, Tanaka K, Konishi T.
    Rinsho Shinkeigaku; 2009 Aug 08; 49(8):457-62. PubMed ID: 19827593
    [Abstract] [Full Text] [Related]

  • 32. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder.
    Lin J, Li X, Xue B, Tong Q, Chen Z, Zhu W, Li J, Xia J.
    J Neuroimmunol; 2018 Apr 15; 317():1-4. PubMed ID: 29501080
    [Abstract] [Full Text] [Related]

  • 33. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study.
    Zhang M, Zhang C, Bai P, Xue H, Wang G.
    Acta Neurol Belg; 2017 Sep 15; 117(3):695-702. PubMed ID: 28608315
    [Abstract] [Full Text] [Related]

  • 34. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
    Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M.
    JAMA Neurol; 2014 Mar 15; 71(3):324-30. PubMed ID: 24445513
    [Abstract] [Full Text] [Related]

  • 35. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M, Zarco LA, Agudelo-Arrieta M, Torres-Camacho I, Garcia-Cifuentes E, Muñoz O.
    Mult Scler Relat Disord; 2021 May 15; 50():102869. PubMed ID: 33711580
    [Abstract] [Full Text] [Related]

  • 36. [Failure of rituximab in relapsing neuromyelitis optica: case report with two-year prospective follow-up].
    Cassinotto C, Joux J, Chausson N, Smadja D, Cabre P.
    Rev Neurol (Paris); 2008 Apr 15; 164(4):394-7. PubMed ID: 18439934
    [Abstract] [Full Text] [Related]

  • 37. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP, Torres-Herrán GE, Miño Zambrano JE, Paredes-Gonzalez V, Caiza-Zambrano FJ.
    Mult Scler Relat Disord; 2021 Feb 15; 48():102683. PubMed ID: 33338945
    [Abstract] [Full Text] [Related]

  • 38. A review of cases of neuromyelitis optica.
    Bomprezzi R, Postevka E, Campagnolo D, Vollmer TL.
    Neurologist; 2011 Mar 15; 17(2):98-104. PubMed ID: 21364364
    [Abstract] [Full Text] [Related]

  • 39. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.
    Chan KH, Ramsden DB, Yu YL, Kwok KH, Chu AC, Ho PW, Kwan JS, Lee R, Lim E, Kung MH, Ho SL.
    Eur J Neurol; 2009 Mar 15; 16(3):310-6. PubMed ID: 19138340
    [Abstract] [Full Text] [Related]

  • 40. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
    Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T.
    Neurology; 2011 Apr 12; 76(15):1310-5. PubMed ID: 21482945
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.